Johnson & Johnson vs Intellia Therapeutics, Inc. — Stock Comparison

JNJ
Johnson & Johnson
$227.19
▼ 1.16%
vs
NTLA
Intellia Therapeutics, Inc.
$13.26
▼ 1.63%
Q·Score Winner
Johnson & Johnson
JNJ7.1/10vs 6.2/10

Q·Score Breakdown

7.1
Bullish
Overall
6.2
Neutral
9.3
Quality
1.6
6.5
Health
9.7
5.1
Growth
7.8
7.3
Valuation
6.9
6.5
Sentiment
6.4
JNJ

High-quality business with 26% return on equity and 22% profit margins.

earnings contracting 53% year-over-year.

NTLA

Clean balance sheet with low leverage (0.1× debt-to-equity).

low return on equity (-53%).

Analyst Consensus

BUY
Target $252.42 (+11.1%)
24 analysts
BUY
Target $26.71 (+101.5%)
21 analysts

Fundamentals

JNJ
NTLA
26.3×
Trailing P/E
17.9×
Forward P/E
-4.6×
21.8%
Profit Margin
0.0%
68.0%
Gross Margin
0.0%
26.4%
ROE
-53.5%
9.9%
Revenue Growth
78.8%
-52.9%
Earnings Growth
0.33
Beta
1.99
Price / Book
$546.9B
Market Cap
$1.6B
$146 – $252
52-Week Range
$7 – $28

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →